Opening Remarks
|
|
Shu Chien received his medical degree from National Taiwan University and Ph.D. in Physiology from Columbia University. He is a University Professor of Bioengineering and Medicine and Director of the Institute of Engineering in Medicine at University of California San Diego. His research focuses on molecular, cellular and integrative bioengineering. He has published over 500 original research papers and edited 14 books. As directors of NIH training grants at Columbia and UCSD since 1975, he has been responsible for the training of hundreds of predoctoral and postdoctoral trainees.
Shu Chien has served in leadership position in many professional organizations, including presidents of American Institute for Medical and Biological Engineering, American Physiological Society, Biomedical Engineering Society, Federation of American Societies of Experimental Biology, International Society of Biorheology, and Microcirculatory Society. He is a member of National Academy of Sciences, National Academy of Engineering, National Academy of Medicine, American Academy of Arts and Sciences, National Academy of Inventors, and Academia Sinica, as well as a foreign member of Chinese Academy of Sciences.
He has received many honors and awards, including Honorary Doctoral Degrees from six universities, Honorary Professorship from 16 universities, the Melville Medal (twice), Fahraeus Medal, Landis Award, ALZA Award, Zweifach Award, Poiseuille Medal, Galletti Award, Revelle Medal, Franklin Medal, Asian American Engineer of the Year, and the Founders Award of National Academy of Engineering. He is a recipient of the National Health Medal and Presidential Prize in Life Sciences in Taiwan, ROC, and the National Medal of Science, the highest honor for scientists and engineers in USA, bestowed by President Obama.
Shu Chien has served in leadership position in many professional organizations, including presidents of American Institute for Medical and Biological Engineering, American Physiological Society, Biomedical Engineering Society, Federation of American Societies of Experimental Biology, International Society of Biorheology, and Microcirculatory Society. He is a member of National Academy of Sciences, National Academy of Engineering, National Academy of Medicine, American Academy of Arts and Sciences, National Academy of Inventors, and Academia Sinica, as well as a foreign member of Chinese Academy of Sciences.
He has received many honors and awards, including Honorary Doctoral Degrees from six universities, Honorary Professorship from 16 universities, the Melville Medal (twice), Fahraeus Medal, Landis Award, ALZA Award, Zweifach Award, Poiseuille Medal, Galletti Award, Revelle Medal, Franklin Medal, Asian American Engineer of the Year, and the Founders Award of National Academy of Engineering. He is a recipient of the National Health Medal and Presidential Prize in Life Sciences in Taiwan, ROC, and the National Medal of Science, the highest honor for scientists and engineers in USA, bestowed by President Obama.
|
|
Richard Y C Chang (張揚展) received his master degree in European studies at Tamkang University, Taiwan in 1979. He joined the Minister of Science and Technology (formerly National Science Council) in 1985 where he has been working since then for international programs. He had been program director for various cooperative programs ranging from European countries, North America, South Africa, Oceanic countries to Russian Federation, etc. He has successfully established scientific collaborations for Taiwan with many countries. He has broad experiences in MOST headquarter as well as in overseas. He has been posted to MOST’s offices abroad in Ottawa of Canada, Chicago of the US and Bonn of Germany. From November 15, 2012, he was assigned as director of Science and Technology Division of the Taipei Economic and Cultural Office in Los Angeles which covers Southern California, Arizona, Colorado, New Mexico, South Dakota, North Dakota, Kansas，Nebraska and Hawaii with a mission to promote bilateral scientific collaborations with Taiwan. He is responsible for 8 states of the U.S. plus Southern California. The main mission of his assignment is to promote bilateral scientific collaborations between Taiwan and the U.S. He speaks fluently English, German, Spanish and French. He is married and has two sons.
Biotech Industry in Taiwan
|
|
Chairman Lu, 路孔明 is the founder of MICROBIO Group and the current Chairman of MICROBIO Group and Diamond BioFund. MIRCOBIO was established in 2000. Ever since then, MICROBIO has become a leading biotechnology company with a strong R&D team that is determined to deliver an extensive portfolio of breakthrough therapeutic products through innovative pipelines and close collaboration with top research leaders and diverse business partners.
MICROBIO has invested over 760 million USD in the development of 12 novel clinical drugs, 2 out of which have passed FDA approval and 8 out of which have progressed into clinical stages. In addition to novel drug discovery, MICROBIO invests in Diamond Biofund Inc. which has become the largest “Evergreen BioFund” in Taiwan with a managing asset of 260 million USD. Diamond BioFund’s existing portfolio has 19 companies. 8 out of the 19 companies have successfully become publicly traded companies. Recent achievements of Diamond BioFund includes assisting Fountain Biopharma Inc. (4159.TT) to acquire Synovel Sciences Inc. in 2017.
MICROBIO and Diamond Biofund strive to improve human health globally through advanced biotechnology.
MICROBIO has invested over 760 million USD in the development of 12 novel clinical drugs, 2 out of which have passed FDA approval and 8 out of which have progressed into clinical stages. In addition to novel drug discovery, MICROBIO invests in Diamond Biofund Inc. which has become the largest “Evergreen BioFund” in Taiwan with a managing asset of 260 million USD. Diamond BioFund’s existing portfolio has 19 companies. 8 out of the 19 companies have successfully become publicly traded companies. Recent achievements of Diamond BioFund includes assisting Fountain Biopharma Inc. (4159.TT) to acquire Synovel Sciences Inc. in 2017.
MICROBIO and Diamond Biofund strive to improve human health globally through advanced biotechnology.
|
|
Mark Kao (高龍榮) went to study at North Carolina State University where he earned his Ph.D in Toxicology. He then did his postdoctoral research at NIH and Cornell University, and worked for Bayer, BASF, American Cyanamid, Wyeth and recently for Janssen (J&J) on the safety issues related to the use of agricultural, animal health and human pharmaceuticals. He is currently Scientific Director at Janssen Research and Development LLC., a subsidiary of J&J. At J&J he works on preclinical development of treatments for rare diseases, cancers, bioterrorism, metabolic and CNS disorders.
Mark is the current President of Taiwanese American Association of Pharmaceutical Sciences (TAAP台美藥劑協會). The main TAAP objectives are to help Taiwanese pharmaceutical industry in Taiwan and to help US-based Taiwanese develop their career (www.TAAP-US.org). Mark is married to Su-Mei with two daughters, Megan and Jennifer.
Mark is the current President of Taiwanese American Association of Pharmaceutical Sciences (TAAP台美藥劑協會). The main TAAP objectives are to help Taiwanese pharmaceutical industry in Taiwan and to help US-based Taiwanese develop their career (www.TAAP-US.org). Mark is married to Su-Mei with two daughters, Megan and Jennifer.
|
|
Dr. Chen presently serves as the Deputy General Director of ITRI Commercialization & Industry Service Center (CIS) and is mainly responsible for helping ITRI new venture business. Also, Dr. Chen currently serves as Deputy Executive Director of Taiwan Innovation Entrepreneurship Center (TIEC), which aims to forge the link with entrepreneurs, venture capital firms and accelerators in Silicon Valley.
Dr. Chen has more than 20 years working experience in Taiwan and abroad. He successively worked for several well-known international enterprises such as being Board of Director of Lippo Group / PT. FIRST MEDIA Tbk, Japan & Northeastern Asia Regional Director of Green Packet Inc. /Berhad and Senior Sales Manager of Compaq Corporation and Control Data Corporation (CDC). Dr. Chen accumulated variety kinds of professional skills in sales and marketing, business models building, operation management and government service. In short, his previous career experience covers all over the lands: China, Taiwan, Hong Kong, Macao, South Korea, Japan, Indonesia, Malaysia, United States, Canada and Europe and he plowed every local markets indeed.
Dr. Chen published four writings. He is the 18th member of Council for Industrial & Commercial Development (CICD) and used to be the chairman of New Generation Entrepreneurs Association (NEA) and the board director of Taiwan Innovative Management Association.
Dr. Chen has more than 20 years working experience in Taiwan and abroad. He successively worked for several well-known international enterprises such as being Board of Director of Lippo Group / PT. FIRST MEDIA Tbk, Japan & Northeastern Asia Regional Director of Green Packet Inc. /Berhad and Senior Sales Manager of Compaq Corporation and Control Data Corporation (CDC). Dr. Chen accumulated variety kinds of professional skills in sales and marketing, business models building, operation management and government service. In short, his previous career experience covers all over the lands: China, Taiwan, Hong Kong, Macao, South Korea, Japan, Indonesia, Malaysia, United States, Canada and Europe and he plowed every local markets indeed.
Dr. Chen published four writings. He is the 18th member of Council for Industrial & Commercial Development (CICD) and used to be the chairman of New Generation Entrepreneurs Association (NEA) and the board director of Taiwan Innovative Management Association.
Academic Research and Industry
|
|
Professor Yuhwa Lo received his PhD in electrical engineering and computer science from UC Berkeley in 1987. He is currently a UCSD professor and the director of the San Diego Nanotechnology Infrastructure (SDNI), one of 16 NSF funded national nanotechnology sites. He also serves the faculty director of the Nano3 facility for California Institute of Telecommunications and Information Technology (Calit2) and the Entrepreneurship and Commercialization Subcommittee for the NSF National Nanotechnology Coordinated Infrastructure (NNCI).
Dr. Lo maintains a broad interest in several research areas, including biomedical devices, point-of- care systems, single-cell technologies, biophotoncs, single-photon detectors, and nanophotonics. He has co-founded 5 companies in biomedical devices and optoelectronics areas, and is currently serving the advisory board of several companies in the areas of biomedical instrument (NanoCellect), medical devices (Nanovision), in-vitro diagnosis (Cellgen DX), next generation sequencing, and biosensors for vital sign detection and health monitoring. He also consulted with a number of large and small companies and served many panels for government, non-profit organizations, and industrial consortiums.
He has published over 400 scientific papers and (co)authored and edited 10 books and special issues. He was awarded 36 patents with nearly 30 applications pending. His inventions have been licensed to a number of companies for commercialization. His earlier inventions in semiconductor materials and optoelectronic devices, including wafer bonding and substrate engineering process for high brightness LEDs, have resulted in sales of over $4B.
He is a fellow of the Optical Society of America (OSA) and the Institute of Electrical and Electronics Engineers (IEEE).
Dr. Lo maintains a broad interest in several research areas, including biomedical devices, point-of- care systems, single-cell technologies, biophotoncs, single-photon detectors, and nanophotonics. He has co-founded 5 companies in biomedical devices and optoelectronics areas, and is currently serving the advisory board of several companies in the areas of biomedical instrument (NanoCellect), medical devices (Nanovision), in-vitro diagnosis (Cellgen DX), next generation sequencing, and biosensors for vital sign detection and health monitoring. He also consulted with a number of large and small companies and served many panels for government, non-profit organizations, and industrial consortiums.
He has published over 400 scientific papers and (co)authored and edited 10 books and special issues. He was awarded 36 patents with nearly 30 applications pending. His inventions have been licensed to a number of companies for commercialization. His earlier inventions in semiconductor materials and optoelectronic devices, including wafer bonding and substrate engineering process for high brightness LEDs, have resulted in sales of over $4B.
He is a fellow of the Optical Society of America (OSA) and the Institute of Electrical and Electronics Engineers (IEEE).
|
|
Dr. Pei-Yu Chiou received his Ph.D. degree in the Electrical Engineering and Computer Sciences Department from the University of California at Berkeley in 2005. He received his M.S. degree in the Electrical Engineering Department from UCLA and B.S. degree in the Mechanical Engineering Department from National Taiwan University in 1998. He was an assistant professor in the Mechanical and Aerospace Engineering Department at the University of California at Los Angeles (UCLA) between 2006~2011, associate professor between 2011~2015, and full professor since then. His research interests focus on optofluidics, biophotonics, Lab on Chip, and flexible devices. He received the NSF CAREER award in 2008, UCLA MAE Teaching Award in 2014, JALA TOP TEN innovation award in 2015. He was elected to the College of Fellows at the American Institute for Medical and Biological Engineering (AIMBE) in 2017. He has 13 awarded and pending US Patents. His inventions have been licensed to few companies for commercialization. He is the co-founder of NanoCav LLC.
Entrepreneurship
|
|
Dr. Sonny Hsiao is Member of the Board of Directors of Adheren Biologics. He became CSO and President of Adheren Biologics in 2015 at the operational inception of the company and built a world class organization to develop new therapies in immune-oncology and cell therapy medicine. During his career at Adheren Biologics, Dr. Hsiao has recruited R&D team, developed company development strategy, and executed on a capital-efficient program to bring company’s lead product from lab research concept through completion of a development program comprising preclinical small animal and non-human primate studies in solid and liquid tumors. The company built unique value by forging its path through a complex and largely unprecedented clinical, regulatory, and commercial landscape.
Dr. Hsiao Co-founded Adheren, Inc in 2010 and has held various roles of responsibility including R&D, Corporate Strategy, and Product Development. The company positioned itself to maximize shareholder value by raising $30M Series A in 2015 from top-tier venture investors, and built strong relationships with the clinical and patient-advocacy community as well as public investors, bankers, and analysts to be both Ph3- and IPO-ready in the event of positive Phase 2 data.
Dr. Hsiao Co-founded Adheren, Inc in 2010 and has held various roles of responsibility including R&D, Corporate Strategy, and Product Development. The company positioned itself to maximize shareholder value by raising $30M Series A in 2015 from top-tier venture investors, and built strong relationships with the clinical and patient-advocacy community as well as public investors, bankers, and analysts to be both Ph3- and IPO-ready in the event of positive Phase 2 data.
|
|
Dr. Tseng is currently a Professor in the Department of Molecular & Medical Pharmacology in David Geffen School of Medicine at UCLA. He also holds memberships in the California NanoSystems Institute, Crump Institute for Molecular Imaging, and Jonsson Comprehensive Cancer Center on the UCLA campus. With continuous support from NCI/NIH via R21, R33, PO1, UO1, and SBIR funding mechanisms over the past decade, his research team has built a unique rare-cell sorting method (a.k.a., NanoVelcro Assays) that enables detection, isolation, and characterization of circulating tumor cells (CTCs) in peripheral blood of cancer patients. Over the past decade, their joint research endeavors have led to a series of NanoVelcro CTC Assays, which have been used to explore the full potential of CTCs as a clinical biomarker, including CTC enumeration, phenotyping, genotyping and expression profiling.
To facilitate the commercial transition of the NanoVelcro Assays, Dr. Tseng founded CytoLumina Technologies Corp., a biotechnology company that has licensed intellectual properties associated with NanoVelcro Assays from UCLA. The company is on a mission to make dramatic improvements in cancer patient quality of life through its patented high sensitivity liquid biopsy nanotechnology for cancer detection and monitoring. CytoLumina’s CTC enumeration assay is currently undergoing an FDA 510(k) medical device clearance for prognostic utility in prostate cancer. In December 2016, CytoLumina was officially invited to participate in White House Cancer Moonshot’s Blood Profiling Atlas in pursuit of accelerating blood profiling diagnostic technologies for the benefit of patient quality of life.
To facilitate the commercial transition of the NanoVelcro Assays, Dr. Tseng founded CytoLumina Technologies Corp., a biotechnology company that has licensed intellectual properties associated with NanoVelcro Assays from UCLA. The company is on a mission to make dramatic improvements in cancer patient quality of life through its patented high sensitivity liquid biopsy nanotechnology for cancer detection and monitoring. CytoLumina’s CTC enumeration assay is currently undergoing an FDA 510(k) medical device clearance for prognostic utility in prostate cancer. In December 2016, CytoLumina was officially invited to participate in White House Cancer Moonshot’s Blood Profiling Atlas in pursuit of accelerating blood profiling diagnostic technologies for the benefit of patient quality of life.
|
|
John Chuang is a talented and innovative executive with variety of experiences in financial services, strategic consulting, and medical device design manufacturing services. He brings wealth of expertise with particular strengths in areas such as global business operations planning, business intelligence optimization, corporate financial planning, mergers and acquisitions (M&A), initial public offerings (IPO), healthcare IT consulting, medical device design manufacturing service, and rapid corporate growth strategy.
With an abundance of international experience, John has a strong understanding of various markets throughout America, Europe, Asia, and the Middle East. Currently, John serves as both Managing Partner on the advisory board of ONYX Group, a professional medical device and IT solution company, and President at ONYX Healthcare USA, Inc. with responsibility to supervise corporate strategy planning, financial forecasting, business operations, OEM/ODM initiative, and comprehensive design manufacturing services.
As a co-founder of ONYX Healthcare USA in 2012, John has rapidly established strategic alliance with more than 40 companies ranging from system integrator, value added reseller, distributors, and OEM manufacturing representative firms to offer FDA certified design manufacturing services for top tier medical device companies across the globe. Under John’s leadership and partner alliance strategy, ONYX Healthcare USA has rapidly established a robust distribution network and doubled its corporate revenue growth starting 2013 which boosted ONYX Group’s global revenue from US$ 6.5 million to US$35 million globally by 2015.
During his time advising ONYX Group, John was also responsible for spearheading go-to-market strategy for ONYX and was instrumental to acquisition of ONYX Group along with its parent corporation, AAEON, by ASUS, the world's 4th-largest PC vendor and Asia’s top 10 IT companies, for over US$ 100 million in 2011. Resulting from ONYX’s rapid growth since 2013, John has taken the initiative with advisory board to take the company public in 2016 to seek for rapid corporate expansion in near future.
Prior to forming ONYX Healthcare, John served as a senior strategy consultant at Accenture and worked with various prestige firms such as JP Morgan Chase, Toyota, Warner Brothers, Hartford, and Well Point Health Insurance etc. to provide strategic consulting service. Under his guidance through various change management and business process redesign initiatives, these firms went through a significant transformation to optimize its business operation efficiency with an average of 22% improvement.
Aside from his executive career at ONYX, John founded Young Professional Exchange (YPEX), a young professional networking group with more than 2,500 members, in 2009 with his partner Samson Yao to hosted series of networking events, workshops, and seminars to enhance professional trainings and cross-industrial networking for young professionals.
John Chuang obtained his Bachelors of Science in Electrical Engineering from Cornell University. He holds a Master of Science degree in Engineering Management from University of Southern California.
With an abundance of international experience, John has a strong understanding of various markets throughout America, Europe, Asia, and the Middle East. Currently, John serves as both Managing Partner on the advisory board of ONYX Group, a professional medical device and IT solution company, and President at ONYX Healthcare USA, Inc. with responsibility to supervise corporate strategy planning, financial forecasting, business operations, OEM/ODM initiative, and comprehensive design manufacturing services.
As a co-founder of ONYX Healthcare USA in 2012, John has rapidly established strategic alliance with more than 40 companies ranging from system integrator, value added reseller, distributors, and OEM manufacturing representative firms to offer FDA certified design manufacturing services for top tier medical device companies across the globe. Under John’s leadership and partner alliance strategy, ONYX Healthcare USA has rapidly established a robust distribution network and doubled its corporate revenue growth starting 2013 which boosted ONYX Group’s global revenue from US$ 6.5 million to US$35 million globally by 2015.
During his time advising ONYX Group, John was also responsible for spearheading go-to-market strategy for ONYX and was instrumental to acquisition of ONYX Group along with its parent corporation, AAEON, by ASUS, the world's 4th-largest PC vendor and Asia’s top 10 IT companies, for over US$ 100 million in 2011. Resulting from ONYX’s rapid growth since 2013, John has taken the initiative with advisory board to take the company public in 2016 to seek for rapid corporate expansion in near future.
Prior to forming ONYX Healthcare, John served as a senior strategy consultant at Accenture and worked with various prestige firms such as JP Morgan Chase, Toyota, Warner Brothers, Hartford, and Well Point Health Insurance etc. to provide strategic consulting service. Under his guidance through various change management and business process redesign initiatives, these firms went through a significant transformation to optimize its business operation efficiency with an average of 22% improvement.
Aside from his executive career at ONYX, John founded Young Professional Exchange (YPEX), a young professional networking group with more than 2,500 members, in 2009 with his partner Samson Yao to hosted series of networking events, workshops, and seminars to enhance professional trainings and cross-industrial networking for young professionals.
John Chuang obtained his Bachelors of Science in Electrical Engineering from Cornell University. He holds a Master of Science degree in Engineering Management from University of Southern California.
Biotech Industry in Southern California
|
|
Feng Tian, Ph. D. has held increasing roles of responsibility since joining Ambrx in 2004. Currently, as Chief Scientific Officer, Dr. Tian oversees company’s research and development. During his tenure at Ambrx, Dr. Tian is instrumental in the establishment and improvement of Ambrx technology and product platforms. He played a key role in the establishment of EuCODE technology platform (site-specific non-natural amino acid incorporation in eukaryotic cells), site-specific antibody drug conjugate (ADC) technology platform and “Life Switch” vaccine platform. More recently, on the business side, Dr. Tian initiated and led the effort in the establishment of Ambrx China Strategy. He played a central role in building China collaborations, and most recently, in Ambrx acquisition by Chinese consortium. Prior to joining Ambrx, Dr. Tian conducted his postdoctoral study at The Scripps Research Institute where his work involved catalytic antibodies, non-natural amino acid incorporation and biosensors etc. Dr. Tian received his Ph. D. in Chemistry from the University of Florida with a dissertation in the field of physical organic chemistry and his B. S. in Chemistry from Peking University.
|
|
Dr. Wang is a diplomate of the American Board of Medical genetics and Genomics (ACMGG) with specialty in Cytogenetics and a fellow of American College of Medical Genetics and Genomics. He received his B.S. and M.S. degrees from National Taiwan University and his MPH and PhD degrees from School of Public Health at the University of California, Los Angeles (UCLA). He completed his clinical fellowships in Cytogenetics and Molecular Genetics at Children’s Hospital of Los Angeles. He currently holds a New York Laboratory Director Certificate of Qualification and a California Clinical Cytogenetics Director’s license.
Before joining Quest Diagnostics Nichols Institute as a Senior Director of Cytogenetics in 2005, Dr. Wang was the former Director of the Center for Medical Genetics & Genetic counseling at Changhua Christian Hospital in Taiwan, and a full professor of Medical Genetics at China Medical University, Tung-Hai University and Chang-Jung University of Taiwan during 2000-2005.
Professor Wang is the lead author of more than 70 peer-reviewed papers, which have been published in various prominent scientific and medical journals.
Before joining Quest Diagnostics Nichols Institute as a Senior Director of Cytogenetics in 2005, Dr. Wang was the former Director of the Center for Medical Genetics & Genetic counseling at Changhua Christian Hospital in Taiwan, and a full professor of Medical Genetics at China Medical University, Tung-Hai University and Chang-Jung University of Taiwan during 2000-2005.
Professor Wang is the lead author of more than 70 peer-reviewed papers, which have been published in various prominent scientific and medical journals.
|
|
Gene Lay, M.S., D.V.M., is Founder, President and CEO of BioLegend, a global life science company headquartered in San Diego. Gene grew up in Taiwan, where he completed his undergraduate studies from National Pingtung University of Science and Technology, School of Veterinary Medicine. Gene pursued graduate study in University of Louisiana, Lafayette. In 1987, he and Ernie Huang co-founded PharMingen. In 1997, PharMingen was acquired by Becton Dickinson, now BD Biosciences PharMingen. After 5 years with BD Biosciences, Gene founded BioLegend in 2002. Gene received the EY Entrepreneur of the Year Award 2016 Life Science in San Diego and National Finalist 2016 in Life Science.
Bench-to-business Workshop
|
|
G.P. Li is the director of the Irvine division of the California Institute for Telecommunications and Information Technology (Calit2), located on the UC Irvine campus. He is also a UCI professor of electrical engineering and computer science, and biomedical engineering. In addition, he directs the campus’s Integrated Nanosystems Research Facility.
His current research interests focus on developing Internet of Things technologies for efficient energy utilization, advanced manufacturing and e-health. Li has published more than 280 research papers involving microelectronic technologies, microwave circuit design, Micro-Electro-Mechanical Systems (MEMS) for communication and biomedical instrumentation applications, and bio-nano-IT technology.
Prior to UCI, Li served as a research staff member and manager of the technology group at IBM’s T. J. Watson Research Center where he worked in the area of VLSI technology and led a research and development team to transfer the technology into the marketplace. In the late 1980s, he chaired a committee charged with defining IBM’s semiconductor technology roadmap beyond the year 2000.
Li holds 24 patents and has started four companies based on his inventions. He was one of four engineering professors honored at the UC Irvine Innovations ceremony in recognition of their significant contributions to the university as inventors and creators. Currently, he directs TechPortal, a technology business incubator housed at the UCI division of Calit2, which supports and nurtures young companies and university researchers commercializing their technologies.
Li received his bachelor’s degree in electrical engineering from National Cheng Kung University (NCKU) in Taiwan, and his master’s and doctorate degrees, also in electrical engineering, from UCLA.
His current research interests focus on developing Internet of Things technologies for efficient energy utilization, advanced manufacturing and e-health. Li has published more than 280 research papers involving microelectronic technologies, microwave circuit design, Micro-Electro-Mechanical Systems (MEMS) for communication and biomedical instrumentation applications, and bio-nano-IT technology.
Prior to UCI, Li served as a research staff member and manager of the technology group at IBM’s T. J. Watson Research Center where he worked in the area of VLSI technology and led a research and development team to transfer the technology into the marketplace. In the late 1980s, he chaired a committee charged with defining IBM’s semiconductor technology roadmap beyond the year 2000.
Li holds 24 patents and has started four companies based on his inventions. He was one of four engineering professors honored at the UC Irvine Innovations ceremony in recognition of their significant contributions to the university as inventors and creators. Currently, he directs TechPortal, a technology business incubator housed at the UCI division of Calit2, which supports and nurtures young companies and university researchers commercializing their technologies.
Li received his bachelor’s degree in electrical engineering from National Cheng Kung University (NCKU) in Taiwan, and his master’s and doctorate degrees, also in electrical engineering, from UCLA.
|
|
Dr. Jennifer Liu, 劉玲君, received her undergraduate degree from National Taiwan University and PhD degree in Chemistry from Texas A&M University studying enzymatic carbohydrate synthesis under the guidance of Dr. Chi-Hui Wong, 翁啟惠, at Scripps Research Institute. Dr. Liu joined Amgen since 1992, and has led analytical sciences, technology working group, and process development teams for Amgen’s innovative product development. She also led the design and implementation of Amgen analytical platforms for monoclonal antibodies. Dr. Liu is currently a member of the Amgen Biosimilars Business Unit, responsible for the overall analytical strategy of Amgen biosimilar products and has represented Amgen in regulatory agency interactions with FDA, EMA, PMDA, CFDA, and Health Canada.
|
|
Han-Yu Chuang is currently a Senior Manager of Bioinformatics at the Oncology Business Unit in Illumina, Inc. She has been the informatics core team lead for Illumina’s first ever clinical-grade comprehensive gene panel products in cancer diagnostics and therapy selection. Beyond leading a group of PhD Bioinformatics Scientists in developing NGS informatics solutions for oncology applications, Han-Yu also serves as technical consultant for other functional teams in assay development, software development, business development, marketing, manufacturing, and regulatory in clinical product development. Another big part of her role is the interaction with key opinion leaders in the oncology field, including pharma partners, to bridge gaps in customer demand and product design. Han-Yu is always thinking ahead for next products in the pipeline to facilitate the realization of precision medicine, so technology scouting for internal and external technology development is also a huge piece in her pursuit.
Prior to joining Illumina, Han-Yu got her PhD degree in Bioinformatics and Systems Biology from University of California, San Diego and her bachelor’s and master’s degree in Computer Science and Information Technology from National Taiwan University. In her past life in academic, she has published more than 20 peer reviewed journal papers in the field of cancer biomarker selection and functional genomics, with in total near to 3,400 citations by research journal papers. Her work has pioneered the use of network based approaches for cancer patient classification and risk stratification.
Prior to joining Illumina, Han-Yu got her PhD degree in Bioinformatics and Systems Biology from University of California, San Diego and her bachelor’s and master’s degree in Computer Science and Information Technology from National Taiwan University. In her past life in academic, she has published more than 20 peer reviewed journal papers in the field of cancer biomarker selection and functional genomics, with in total near to 3,400 citations by research journal papers. Her work has pioneered the use of network based approaches for cancer patient classification and risk stratification.
|
|
Dr. Peng Chen leads his biotechnology, pharmaceutical, and diagnostics clients through the technical and legal challenges involved in developing and protecting their critical IP assets. Dr. Chen’s practice focuses on patent prosecution and counseling, and he is also experienced in the areas of patent litigation, reexamination, interference, opposition, and licensing.
For numerous clients, Dr. Chen manages entire patent portfolios, advising the clients on maximizing their patent positions and designing patent strategies. On behalf of one client, he obtained U.S. patent protection for its novel diagnostic test and advised the client in designing around a third party’s patents. When the third party threatened to sue the client, he worked with several Morrison & Foerster patent litigators in obtaining summary judgments of non-infringement twice from the District Court and eventually won the appeal from the Federal Circuit.
In another case, Dr. Chen worked with a team of litigation attorneys, successfully reversing a summary judgment of infringement and eventually obtaining a jury verdict of non-infringement for the client in the District Court. After the case was remanded to the District Court, he filed reexamination request of the claims asserted by the patentee to the USPTO. The Board of Patent Appeals and Interferences (Board) in the USPTO invalidated the claims, and the Federal Circuit affirmed the Board’s decision.
While earning his B.S., Dr. Chen was on the Dean’s List. After receiving his Ph.D., Dr. Chen conducted his post-doctoral fellowship at Yale University School of Medicine. He was also a Harlan Fiske Stone Scholar while in law school.
For numerous clients, Dr. Chen manages entire patent portfolios, advising the clients on maximizing their patent positions and designing patent strategies. On behalf of one client, he obtained U.S. patent protection for its novel diagnostic test and advised the client in designing around a third party’s patents. When the third party threatened to sue the client, he worked with several Morrison & Foerster patent litigators in obtaining summary judgments of non-infringement twice from the District Court and eventually won the appeal from the Federal Circuit.
In another case, Dr. Chen worked with a team of litigation attorneys, successfully reversing a summary judgment of infringement and eventually obtaining a jury verdict of non-infringement for the client in the District Court. After the case was remanded to the District Court, he filed reexamination request of the claims asserted by the patentee to the USPTO. The Board of Patent Appeals and Interferences (Board) in the USPTO invalidated the claims, and the Federal Circuit affirmed the Board’s decision.
While earning his B.S., Dr. Chen was on the Dean’s List. After receiving his Ph.D., Dr. Chen conducted his post-doctoral fellowship at Yale University School of Medicine. He was also a Harlan Fiske Stone Scholar while in law school.
|
|
Chris Loryman is a technology manager with experience across a range of industries, in the US and Europe. Before joining the Office of Innovation & Commercialization as a Senior Licensing Officer, Chris was a Principal Contract Officer at UC San Diego, with delegated authority to negotiate and sign agreements on behalf of the Regents of the University of California. Focusing on researcher-initiated science projects and early-phase clinical trials, he secured more than $15 million in new research funding.
Initially trained in biochemistry, Chris worked in industry, and was part of the Smith & Nephew team acquiring the assets of Advanced Tissue Sciences following their Chapter 11 filing. Relocating to the United States he took charge of the Tissue Engineering Research Laboratory in La Jolla California, working on the development of several products and key publications. Transferring into clinical research, he ran a 25-country, 500-patient, Phase 3b oncology study of maintenance therapy in Non-Hodgkin’s Lymphoma. Following this he moved into early-phase technology development at UCL Business PLC, the technology development company of University College London (one of the top ten universities in the world, by QS ranking). Over five years he built a pipeline of two Phase 2, one Phase 1, and two late-stage pre-clinical assets, and secured over $24.8 million in translational research funding. In 2009 he founded ThioLogics, a biopharmaceutical company with a portfolio of antibody-drug conjugate technologies, before joining UC San Diego in June 2013.
Initially trained in biochemistry, Chris worked in industry, and was part of the Smith & Nephew team acquiring the assets of Advanced Tissue Sciences following their Chapter 11 filing. Relocating to the United States he took charge of the Tissue Engineering Research Laboratory in La Jolla California, working on the development of several products and key publications. Transferring into clinical research, he ran a 25-country, 500-patient, Phase 3b oncology study of maintenance therapy in Non-Hodgkin’s Lymphoma. Following this he moved into early-phase technology development at UCL Business PLC, the technology development company of University College London (one of the top ten universities in the world, by QS ranking). Over five years he built a pipeline of two Phase 2, one Phase 1, and two late-stage pre-clinical assets, and secured over $24.8 million in translational research funding. In 2009 he founded ThioLogics, a biopharmaceutical company with a portfolio of antibody-drug conjugate technologies, before joining UC San Diego in June 2013.
|
|
Ya-Ling Wu is an intellectual property attorney with a focus on biotechnology and life sciences patent counseling. She is currently Intellectual Property Counsel at Quest Diagnostics, where she oversees various aspects of intellectual property and related business matters. At Quest Diagnostics, Ya-Ling develops, manages and enforces global patent portfolios, and performs patentability, validity and freedom-to-operate analyses. She supports various teams in the company to formulate and implement strategies to mitigate risks as well as to protect and leverage intellectual property. Her responsibilities also include due diligence activities in connection with test development, licensing, strategic collaborations and business development of the company. Before joining Quest Diagnostics in 2012, she was a patent attorney at Jones Day for several years where she advised clients on patent prosecution and counseling in the areas of stem cell therapy, immunology, molecular biology, medical diagnostics, and drug development.
Prior to her legal career, Ya-Ling studied and worked as a scientist for 15 years in a broad range of fields such as structural biology, oncology, biochemistry, molecular biology, and immunology. Ya-Ling received her J.D. degree from University of Washington, her Ph.D. degree in Biochemistry and Molecular Biology from the University of Chicago, and her master’s and bachelor’s degrees from National Taiwan University.
Prior to her legal career, Ya-Ling studied and worked as a scientist for 15 years in a broad range of fields such as structural biology, oncology, biochemistry, molecular biology, and immunology. Ya-Ling received her J.D. degree from University of Washington, her Ph.D. degree in Biochemistry and Molecular Biology from the University of Chicago, and her master’s and bachelor’s degrees from National Taiwan University.
